TAX1BP3 and Guillain-Barre syndrome: Accordingly, TIP1 can be a promising new anti-inflammatory drug candidate for the treatment of inflammatory diseases such as sepsis and autoimmune diseases, including RA, systemic lupus erythematosus, inflammatory bowel disease, multiple sclerosis, type 1 diabetes mellitus, Guillain-Barre syndrome, chronic inflammatory demyelinating polyneuropathy, or psoriasis.